CD274 and cancer: iRGD (CRGDKGPD)-decorated, pH-responsive liposomes co-encapsulating lenvatinib and the small-molecule PD-1/PD-L1 inhibitor BMS achieved vascular normalization, reduced Tregs and MDSCs, promoted CD8+ T cell infiltration, and upregulated PD-L1 expression on cancer cells[168].